Ara 290 vs Testosterone
Extensively Studied vs FDA Approved
monitor Mechanism-based · 65% Both Ara 290 and Testosterone can elevate hematocrit/RBC count. Combined use increases risk of polycythemia and thrombotic events. Monitor CBC regularly — donate blood if hematocrit exceeds 54%.
Molecular Data
Ara 290 Testosterone
Weight 1,257 Da 288.42 Da (base)
Half-life ~20 minutes (SubQ), ~2 minutes (IV) ~8 days (cypionate)
Chain 11 amino acids —
Type Engineered peptide Steroid hormone (C19H28O2)
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
Testosterone
01 Restoration of normal testosterone levels in hypogonadal men
02 Increased lean muscle mass and strength
03 Improved bone mineral density and reduced fracture risk
04 Enhanced libido, sexual function, and erectile quality
05 Improved mood, energy, motivation, and cognitive clarity
06 Reduction in body fat percentage, particularly visceral fat
07 Increased red blood cell production and oxygen-carrying capacity
08 Improved insulin sensitivity and metabolic health markers
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
Testosterone
100-200 mg/week (TRT) / 1-2x per week (injectable)
TRT - Standard Replacement 100-200 mg/week 1-2x per week
TRT - Conservative Start 80-100 mg/week 2x per week (40-50 mg per injection)
TRT - Propionate Protocol 25-50 mg every other day Every other day or 3x per week
Performance Enhancement - Moderate 300-500 mg/week 2x per week
Performance Enhancement - Advanced 500-750 mg/week 2-3x per week
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
Testosterone
Acne and oily skin (increased sebum production via DHT)
Water retention and bloating (estrogen-mediated)
Mild mood changes (irritability, increased assertiveness)
Increased hematocrit and hemoglobin (erythrocytosis)
Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
Injection site pain, redness, or irritation
Increased body hair growth
Mild elevation in blood pressure
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled severe heart failure
Untreated severe obstructive sleep apnea
Desire for near-term fertility (without concurrent HCG/FSH)
Pregnancy or potential exposure to pregnant women (Category X)
Hypersensitivity to testosterone or any formulation components
Research Evidence
Ara 290 Testosterone
Status Extensively Studied FDA Approved
References 5 studies 5 studies
Latest 2024 June 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.